Self-emulsifying composition of ω3 fatty acid

Patent metadata

Field	Value
Publication number	US-9801843-B2
Application number	US-201414905520-A
Country	US
Kind code	B2
Filing date	Jul 17, 2014
Priority date	Jul 18, 2013
Publication date	Oct 31, 2017
Grant date	Oct 31, 2017

Abstract

A self-emulsifying composition contains: 70 to 90% by weight in total of one or more compounds selected from the group consisting of ω3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; 1 to 29% by weight of an emulsifying agent selected from among a polyoxyethylene sorbitan fatty acid ester, a sorbitan fatty acid ester, a glycerin fatty acid ester and a polyoxyl castor oil; and 0.5 to 6% by weight of water when the composition is defined to be 100% by weight as a whole. The self-emulsifying composition is excellent in self-emulsifying property, composition dispersibility, emulsion stability, and absorbability, is free from ethanol and polyhydric alcohols or only has such an alcohol added thereto at a reduced concentration, and is useful for foods and pharmaceuticals.

First claim

The invention claimed is:

1. A self-emulsifying composition comprising, when the self-emulsifying composition is defined to be 100% by weight as a whole,
a) 70 to 90% by weight of at least one compound selected from the group consisting of ω3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters,
b) 0.5 to 6% by weight of water, and
c) 1 to 29% by weight of an emulsifying agent including either
i) a polyoxyethylene sorbitan fatty acid ester or
ii) at least two members selected from the group consisting of a sorbitan fatty acid ester, a glycerin fatty acid ester and a polyoxyethylene castor oil, or

1 to 29% by weight of an emulsifying agent including
i) a polyoxyethylene sorbitan fatty acid ester and
ii) at least one member selected from the group consisting of a sorbitan fatty acid ester, a glycerin fatty acid ester and a polyoxyethylene castor oil, wherein

d) content of ethanol is up to 4% by weight of the whole composition, and
e) content of polyhydric alcohol is up to 4% by weight of the whole composition,
wherein the composition is free from separation and cloudiness and maintains good appearance when stored at a temperature of 5° C. for 12 hours or at a temperature of 40° C. for 12 hours.

2. The self-emulsifying composition according to claim 1 , wherein the ω3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters include at least one member selected from the group consisting of EPA, DHA, and their pharmaceutically acceptable salts and esters.

3. The self-emulsifying composition according to claim 1 , wherein the polyhydric alcohol is propylene glycol or glycerin.

4. The self-emulsifying composition according to claim 1 , wherein the content of the ethanol is up to 1% by weight of the whole composition.

5. The self-emulsifying composition according to claim 1 , wherein the content of the polyhydric alcohol is up to 1% by weight of the whole composition.

6. The self-emulsifying composition according to claim 1 , wherein said self-emulsifying composition further comprises lecithin, wherein a content of lecithin in the composition is less than 3 parts by weight in relation to 100 parts by weight of the at least one compound selected from the group consisting of ω3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters.

7. A capsulated self-emulsifying preparation having a self-emulsifying composition held in a capsule as a liquid content, with the self-emulsifying composition comprising, when the self-emulsifying composition is defined to be 100% by weight as a whole,
a) 70 to 90% by weight of at least one compound selected from the group consisting of ω3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters,
b) 0.5 to 6% by weight of water, and
c) 1 to 29% by weight of an emulsifying agent including either
i) a polyoxyethylene sorbitan fatty acid ester or
ii) at least two members selected from the group consisting of a sorbitan fatty acid ester, a glycerin fatty acid ester and a polyoxyethylene castor oil, or

1 to 29 % by weight of an emulsifying agent including
i) a polyoxyethylene sorbitan fatty acid ester and
ii) at least one member selected from the group consisting of a sorbitan fatty acid ester, a glycerin fatty acid ester and a polyoxyethylene castor oil,

and having
d) an ethanol content which is up to 4% by weight of the whole composition, and
e) a polyhydric alcohol content which is up to 4% by weight of the whole composition,
wherein the capsule is a hard capsule and/or a soft capsule,
wherein the composition is free from separation and cloudiness and maintains good appearance when stored at a temperature of 5° C. for 12 hours or at a temperature of 40° C. for 12hours.

8. The capsulated self-emulsifying preparation according to claim 7 , wherein a capsule film of the soft capsule contains gelatin.

9. The self-emulsifying composition according to claim 2 , wherein the polyhydric alcohol is propylene glycol or glycerin.

10. The self-emulsifying composition according to claim 9 , wherein the content of the ethanol is up to 1% by weight of the whole composition.

11. The self-emulsifying composition according to claim 10 , wherein said self-emulsifying composition further comprises lecithin, wherein a content of lecithin in the composition is less than 3 parts by weight in relation to 100 parts by weight of the at least one compound selected from the group consisting of ω3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters.

12. The self-emulsifying composition according to claim 2 , wherein said self-emulsifying composition further comprises lecithin, wherein a content of lecithin in the composition is less than 3 parts by weight in relation to 100 parts by weight of the at least one compound selected from the group consisting of ω3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters.

Assignees

• Mochida Pharm Co Ltd

Inventors

• Kimura Shigeru
• Ito Hiromitsu
• Fujii Hirosato
• Yamagata Motoo

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P7/02

  Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title

• A61P3/06

  Antihyperlipidemics · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title